Skip to main content

Barclays Remains a Buy on Omada Health, Inc. (OMDA)

Tipranks - Tipranks - Tue Jan 6, 4:00AM CST

In a report released today, Saket Kalia from Barclays maintained a Buy rating on Omada Health, Inc., with a price target of $22.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Kalia is a 5-star analyst with an average return of 9.6% and a 56.79% success rate. Kalia covers the Technology sector, focusing on stocks such as Varonis Systems, Tenable Holdings, and Adobe.

Omada Health, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $28.14.

See today’s best-performing stocks on TipRanks >>

Based on Omada Health, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $68.03 million and a GAAP net loss of $3.18 million. In comparison, last year the company earned a revenue of $35.1 million and had a GAAP net loss of $18.97 million

Read More on OMDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).